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In several cell types 1,25_dihydroxyvitamin Da(1,25(OH)*D,) causes up-regulation of its receptor. The present study demonstrates that in the os- 
teoblast-like cell line UMR 106 this up-regulation is inhibited by two different calcium channel blockers (nitrendipine, verapamil). Also with chelat- 
ing extracellular calcium (EGTA) and by inhibition of calcium release from intracellular stores (TMB-8) comparable results were obtained. These 
findings indicate that calcium is functionally involved in this cellular response to the steroid hormone 1,25(OHXD,. Moreover, data obtained with 
EGTA show that the l,ZS(OHXD, receptor level is closely regulated by the extracellular calcium concentration. 
1,25-Dihydroxyvitamin D3; Calcium; 1,25(0H)zDs receptor up-regulation 
1. INTRODUCTION 
1,25_Dihydroxyvitamin D3 (1,25(OH)~D3) is an im- 
portant regulator of calcium homeostasis and bone 
metabolism. It has been shown that 1,25(OH)~D3 
causes homologous up-regulation of its receptor in the 
osteoblast-like cell lines ROS 17/2 [l] and UMR 106 [2], 
and in fibroblasts and cloned kidney cells [3]. 
The occupied 1,25(OH)zD3 receptor is thought to act 
direct at the genome. However, in various cellular 
systems 1,25(OH)zD3 has been shown to stimulate 
calcium uptake independent of de novo RNA and pro- 
tein synthesis [4-61, and genome independent effects on 
membrane potential have been reported [7]. Also, 
recently it has been demonstrated that 1,25(OH)zD3 
causes a rapid (less than 30 s) rise of the intracellular 
ionized calcium concentration ([Ca2+]i) in isolated 
mouse osteoblasts [8]. The 1,25(OH)zD3-induced rise of 
the [Ca’+]i has been shown to be inhibited by the 
calcium channel blockers nifedipine and verapamil, by 
chelating extracellular calcium with EGTA and to be 
reduced by blocking release from intracellular stores by 
%(diethylamino)octyl 3,4,5-trimethoxybenzoate HCl 
(TMB-8) [8]. In the osteoblast-like cell line ROS 17/2.8 
1,25(OH)zD3 modulates dihydropyridine-sensitive L- 
type calcium channels [9]. Moreover, in keratinocytes 
and rat enterocytes 1,25(OH)~D3 increases the genera- 
tion of inositol 1,4,5-trisphosphate indicating an effect 
on calcium release from intracellular stores [lo, 111. 
Correspondence address: J.P.T.M. van Leeuwen, Department of In- 
ternal Medicine III, Erasmus University Medical School, PO Box 
1738, 3000 DR Rotterdam, The Netherlands 
Based on these data it is conceivable that calcium acts as 
an intracellular messenger in the regulation of cellular 
responses by 1,25(OH)zD3. However, as yet a func- 
tional role for calcium has to be demonstrated. 
In the present study we have investigated whether 
calcium is functionally involved in 1,25(OH)zDs-in- 
duced up-regulation of its receptor in the osteoblast-like 
cell line UMR 106. 
2. MATERIALS AND METHODS 
2.1. Materials 
Verapamil and EGTA were obtained from Sigma, St. Louis, USA, 
TMB-8 from Aldrich Chemical Co., Bruxelles, Belgium. Nitrendipine 
was a generous gift from Dr B. Garthoff of Bayer AG, Wuppertal, 
FRG. [23,24-‘H] 1,25(OH)zD~ (90 Ci/mmol) was purchased from 
Amersham International, Amersham, UK, and non-radioactive 
1,25(OH)zD, was generously provided by LEO Pharmaceuticals BV, 
Weesp, The Netherlands. 
2.2. Culture and treatment of the cells 
UMR 106 cells were cultured as described previously [12]. The cells 
were incubated for 4 h with or without 1,25(OH)zD, in the absence or 
presence of nitrendipine, verapamil, EGTA, or TMB-8. 
2.3. Preparation of cell extracts and 1,25(OH)~Dj binding assay 
For single point assays, conditions were employed which were 
previously shown to provide valid estimates of total VDR content in 
cytosolic extracts [2]. The protein concentration was measured accor- 
ding to the method of Bradford [13]. 
2.4. Data analysis 
Data presented are means f SD of triplicate determinations of at 
least 2 different experiments, i.e. at least 6 replicates. Interactions bet- 
ween 1,25(OH)~Ds and calcium antagonists were evaluated using an 
analysis of variance for 2-way factorial design [14]. Other statistical 
analyses were done by Student’s t-test. 
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Table I 
Effect of chelating extracellular calcium with ECiTA and blocking calcium release 
from intracellular stores by TMB-8 on homologous up-re~lation of VDR. Data 
expressed as fmol ['Hf 1,25(OH)zD3 boundlmg protein. 
[1,25KWD31 Control 1.5 mM EGTA 2 mM EGTA TMB-8 _-. 
0 254 zt 1.3 23.5 f 0.2 45.0 + 1.6* 19.7 + 0.8** 
lo- lo M 40.6 f 1.8’ 40.4 rt 1.6 45.8 f 0.9~ v 29.7 f 1.01 
JO-” M 106.8 + 3.4* 105.9 f 4.3 82.0 f 2.1# 64.3 f 1.1 m 
*P<O.oOl, **P, 0.05 with respect o basal YDR content (25.4 f 1.3). v PcO.05, 
v v PC 0.002 and 6 P< 0.001 calculated as the significance of interaction between 
1,25(OH)rDr and EGTA 
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3. RESULTS AND DISCUSSION 
To our knowledge this is the first report showing a 
direct functional involvement of calcium as in- 
tracellular signal in a cellular response to 1,25(OH)zD3. 
Basal 1,25(OH)zD3 binding was significantly reduced 
by the calcium channel blockers nitrendipine (5 x 10m5 
M, P<O.O5) and verapamil (10m4M, P<O.OOl) 1121. 
With 1.5 mM EGTA no effect was observed whereas 2 
mM EGTA induced an increase in VDR level (Table I). 
Recently it was reported that expression of murine 
epidermal differentiation markers is tightly regulated 
by restricted extracellular calcium concentrations [151. 
In our study basal medium calcium concentration was 
1.42 mM and in the presence of 1.5 and 2 mM EGTA 
0.28 and 0.05 mM, respectively. These concentrations 
are in the same range as those reported to be important 
for the expression of epidermal differentiation markers 
[15]. Therefore it is likely that basal VDR level is also 
tightly regulated by extracellular calcium concentra- 
tions. Moreover, preliminary data obtained in our 
laboratory show an increase of VDR mRNA by 2 mM 
but not by 1.5 mM EGTA (manuscript in preparation). 
As depicted in Figs. 1 and 2, VDR up-regulation by 
IO- lo M 1,25(OH)~D3 is significantly reduced by lo- 5 
and 5 x 10v5 M nitrendipine (18 and 48% inhibition) 
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Fig. I. Effect of nitrendipine on homologous up-regulation of VDR. 
5 x IO-’ M nitrendipine significantly (P~0.05) reduced basal 
1,25(OH)rDs binding. **P<O.O25; *P<O.OOl calculated as the 
significance of interaction between 1,25(OH)rDs and nitrendipine. 
Fig. 2. Effect of verapamil on homologous up-regulation of VDR. 
10-4 M verapamil significantly (PcO.001) reduced basal 
1,25(OHhDs binding. **PC 0.01, *PC 0.0025 calculated as the 
significance of interaction between 1,25(OH)rDs and verapamii. 
and by 10 - 5 and 10 - 4 M verapamil(24 and 50% inhibi- 
tion). In contrast, low8 M 1,25(OH)2D3*induced VDR 
up-regulation is not affected by IO- ’ M nitrendipine 
and lo-’ M verapamil and only 30% and 40% reduc- 
tion was observed with 5 x 10 - ’ M nitrendipine and 
10m4 M verapamil, respectively (Figs. 1 and 2). 
Together with the results obtained with EGTA (Table 
I), these data indicate that calcium is functionary in- 
volved in homologous up-regulation of VDR in UMR 
106 cells. Recently we demonstrated that calcium is also 
involved in heterologous up-regulation of VDR [ 121. 
A role for intracellular calcium stores in the action of 
1,25(OH)zD3 is indicated by the data obtained with 0.1 
mM TMBd (Table I). VDR up-regulation by 10 - lo and 
lo-’ M 1,25(OH)zD3 was inhibited by 34 and 45Y0, 
respectively. This is in agreement with the reports show- 
ing effects of 1,25(OH)aD3 on the phosphoinositide 
metabolism [ 10,111. 
Both verapamil and nitrendipine inhibited IO-” M 
1,25(OH)2D3-induced VDR up-regulation at a lower 
concentration and with a greater magnitude than the 
up-regulation by lo-* M 1,25(OH)zD3 (Figs. 1 and 2). 
It is unlikely that this is due to the fact that the increase 
of the [Ca’+]t by 10e8 M is more pronounced than the 
increase by 10-i’ M 1,25(OHhD3. As Lieberherr [8] 
reported that a maximum increase of [Ca2+]i was 
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observed at lo- lo M whereas 10e8 M, 1,25(OH)zD~ has 
only a minor effect on the [Ca2+]i. Moreover, Caffrey 
and Farach-Carson [9] reported agonistic (0.05-5 nM) 
and antagonistic (> 10 nM) effects on calcium currents. 
Based on the current data it is tempting to suggest hat 
1,25(0H)~D~ causes VDR up-regulation both depen- 
dent on and independent of an increase of the [Ca’+]i, 
and that the calcium dependency is more prominent at 
low than at high 1,25(OH)zD3 concentrations. 
Although Bloor et al. [16] have reported detectable 
levels of 1,25(OH)zD3 in intestinal nuclei 5 min after ad- 
ministration it is, in view of the fast effect of 
1,25(OH)zD3 on the [Ca’+]i, unlikely that the effect of 
1,25(OH)zD3 on the [Ca’ +]i is exerted via the genome. 
Whether 1,25(OH)zD3 exerts its effects on [Ca2+]i via a 
cell surface receptor is not yet clear, although recent 
data point to a cell surface receptor for 1,25(OH)zD3 
[l l] and a steroid receptor has been identified on the 
surface of Xenopus oocytes [17]. 
Taken together, the current study demonstrates (1) a 
role for the extracellular calcium concentration in the 
regulation of the VDR level, and (2) a functional 
messenger role for intracellular calcium in the action of 
1,25(OH)zD3 in osteoblast-like cells and thereby pro- 
vides new insights in the mechanism of action of this 
steroid hormone. 
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